Navigation Links
Pasteuria Bioscience to be Acquired by Syngenta
Date:9/19/2012

ALACHUA, Fla., Sept. 19, 2012 /PRNewswire/ -- Pasteuria Bioscience has announced that it will be acquired by Syngenta, one of the world's leading agricultural technology companies.  In 2011 Syngenta and Pasteuria Bioscience entered into a global exclusive technology partnership to produce nematode control products based on Pasteuria spp., a naturally-occurring soil bacteria long recognized as a promising biological control agent against nematodes.  The first products resulting from this relationship will be available in 2014.

Under terms of the agreement, Syngenta will acquire Pasteuria Bioscience for aggregate payments of $86 million, plus up to $27 million in deferred payments.

"Pasteuria Bioscience is excited to become part of the Syngenta team.  We've been working closely together over the past year and have made significant progress on a number of nematode control products in a variety of crops.  Syngenta recognizes the potential with the Pasteuria platform and can commercialize it in a broad range of products for the global marketplace," said Al Kern, Executive Chairman and President of Pasteuria Bioscience.

Nematodes are a major pest across all crops and there are few commercial products available making it one of agriculture's largest unmet pest control needs.  This acquisition will facilitate the introduction of key products, including a seed treatment product for Soybean Cyst Nematode (SCN) which will complement Syngenta's existing nematicide line. 

"Results from our partnership have shown that Pasteuria provides superior control of nematodes in a wide variety of applications.  Pasteuria Bioscience has developed critical knowhow for in vitro production of Pasteuria, enabling commercial scale manufacturing.  This is a further example of our strategy to incorporate biological controls within our integrated offer to growers," said John Atkin, COO of Syngenta.

About Pasteuria Bioscience

Pasteuria Bioscience, Inc., was founded in 2003 in the University of Florida's Sid Martin Biotechnology Incubator where it remains headquartered.  The company was developed to commercialize its revolutionary technology for production of biological nematode control products based on the Pasteuria platform.  The first Pasteuria-based product, Econem®, was commercialized in 2010 for sting nematode control in the golf and sports turf markets.  Pasteuria Bioscience is also developing products to treat major nematode pests in most agricultural crops such as soybean, sugar beet and cotton as well as in specialty crops such as fruits and vegetables.  For more information, visit the Pasteuria Bioscience web site at http://www.pasteuriabio.com.

Note to the editor:

Learn more about Syngenta http://www.syngenta.com.


'/>"/>
SOURCE Pasteuria Bioscience
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Syngenta to acquire Pasteuria Bioscience
2. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
3. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
4. Kansas Bioscience Authority Announces FY11 Outcomes of $207 Million
5. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
6. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
7. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
8. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
9. Ohios Bioscience Industry Effort Paying Off With Increase in Graduates and Accolades for the State
10. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
11. Roka Bioscience Secures $47.5 Million in Series D Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 27, 2016 , ... Cancer experts from Austria, Hungary, Switzerland, ... a new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has just ... now. , Biomarkers are components in the blood, tissue or body fluids ...
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
Breaking Biology Technology:
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
Breaking Biology News(10 mins):